Metabolic Dysfunction-Associated Steatotic Liver Disease Is Characterized by Enhanced Endogenous Cholesterol Synthesis and Impaired Synthesis/Absorption Balance
- PMID: 40806589
- PMCID: PMC12347333
- DOI: 10.3390/ijms26157462
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Characterized by Enhanced Endogenous Cholesterol Synthesis and Impaired Synthesis/Absorption Balance
Abstract
Cholesterol accumulation plays a significant role in the pathogenesis of metabolic-dysfunction-associated steatotic liver disease (MASLD), yet changes in cholesterol homeostasis in MASLD remain insufficiently investigated. This study aimed to examine alterations in cholesterol synthesis and absorption by measuring plasma levels of endogenous cholesterol precursors (as markers of synthesis) and phytosterols (as indicators of absorption). A total of 124 MASLD patients and 43 healthy individuals were included. Our results showed higher plasma concentrations of lathosterol in the MASLD group (p = 0.006), in parallel with comparable concentrations of desmosterol (p = 0.472) and all analyzed phytosterols in both groups. Correlation analysis showed that both lathosterol and desmosterol were positively associated with non-invasive hepatic steatosis indices: FLI, HSI, and TyG index (p < 0.01, p < 0.01, and p < 0.05, respectively). Multivariate linear regression further confirmed that these synthesis markers remained significant predictors of FLI (p = 0.010), HSI (p = 0.013), and TyG index (p = 0.002), even after adjusting for other relevant variables. These findings indicate that MASLD is associated with a shift in cholesterol homeostasis towards enhanced endogenous cholesterol synthesis.
Keywords: MASLD; cholesterol homeostasis; dietary cholesterol absorption; endogenous cholesterol synthesis; hepatic steatosis indices; non-cholesterol sterols.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Similar articles
-
Metabolic Dysfunction-Associated Steatotic Liver Disease (MΑSLD).2025 Aug 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Aug 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31082077 Free Books & Documents.
-
Serum Tsukushi level is negatively associated with cholesterol efflux capacity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.Sci Rep. 2025 Jul 1;15(1):21883. doi: 10.1038/s41598-025-06431-w. Sci Rep. 2025. PMID: 40596096 Free PMC article.
-
Association of dietary inflammatory index with liver fibrosis and fatty liver index in a population with metabolic dysfunction-associated steatotic liver disease: A cross-sectional study.Front Nutr. 2025 Jun 24;12:1594192. doi: 10.3389/fnut.2025.1594192. eCollection 2025. Front Nutr. 2025. PMID: 40630170 Free PMC article.
-
Association of triglyceride glucose-body mass index (TyG-BMI) with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.PLoS One. 2025 Aug 4;20(8):e0324483. doi: 10.1371/journal.pone.0324483. eCollection 2025. PLoS One. 2025. PMID: 40758732 Free PMC article.
-
Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.Cochrane Database Syst Rev. 2025 Jun 24;6(6):CD015524. doi: 10.1002/14651858.CD015524.pub2. Cochrane Database Syst Rev. 2025. PMID: 40552569
References
-
- Younossi Z.M., Razavi H., Sherman M., Allen A.M., Anstee Q.M., Cusi K., Friedman S.L., Lawitz E., Lazarus J.V., Schuppan D., et al. Addressing the High and Rising Global Burden of Metabolic Dysfunction—Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction—Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors’ Perspective. Aliment. Pharmacol. Ther. 2025;61:1467–1478. doi: 10.1111/apt.70020. - DOI - PubMed
-
- Lu Y., Xu X., Wu J., Ji L., Huang H., Chen M. Association between Neutrophil-To-High-Density Lipoprotein Cholesterol Ratio and Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis in the US Population: A Nationally Representative Cross-Sectional Study Using NHANES Data from 2017 to 2020. BMC Gastroenterol. 2024;24:300. doi: 10.1186/s12876-024-03394-6. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical